{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Standard+Care+Control&page=2",
    "query": {
      "condition": "Standard Care Control",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Standard+Care+Control&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-24T03:09:18.441Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02790632",
      "title": "Study of EG-1962 Compared to Standard of Care Oral Nimodipine in Adults With Aneurysmal Subarachnoid Hemorrhage",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Subarachnoid Hemorrhage, Aneurysmal"
      ],
      "interventions": [
        {
          "name": "EG-1962 (nimodipine microparticles)",
          "type": "DRUG"
        },
        {
          "name": "Enteral Nimodipine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Edge Therapeutics Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 374,
      "start_date": "2016-07",
      "completion_date": "2018-06",
      "has_results": false,
      "last_update_posted_date": "2018-07-26",
      "last_synced_at": "2026-07-24T03:09:18.441Z",
      "location_count": 45,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 32 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02790632"
    },
    {
      "nct_id": "NCT04079998",
      "title": "Procellera® Compared to Standard of Care Treatment in Mitigating Biofilm Formation in Acute Trauma and Burn Wounds",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Trauma-related Wound",
        "Burn, Partial Thickness"
      ],
      "interventions": [
        {
          "name": "Procellera®",
          "type": "DEVICE"
        },
        {
          "name": "Standard of Care",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "OTHER"
      ],
      "sponsor": "The Metis Foundation",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 38,
      "start_date": "2019-02-28",
      "completion_date": "2020-12-03",
      "has_results": false,
      "last_update_posted_date": "2021-01-22",
      "last_synced_at": "2026-07-24T03:09:18.441Z",
      "location_count": 1,
      "location_summary": "Fort Sam Houston, Texas",
      "locations": [
        {
          "city": "Fort Sam Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04079998"
    },
    {
      "nct_id": "NCT04673344",
      "title": "Regeneten Patch vs Standard Care in Partial Thickness Rotator Cuff Repair",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Rotator Cuff Tears",
        "Shoulder Surgery"
      ],
      "interventions": [
        {
          "name": "Regeneten Collagen Patch",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Rothman Institute Orthopaedics",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "40 Years to 75 Years"
      },
      "enrollment_count": 80,
      "start_date": "2020-12-30",
      "completion_date": "2021-12-31",
      "has_results": false,
      "last_update_posted_date": "2020-12-17",
      "last_synced_at": "2026-07-24T03:09:18.441Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04673344"
    },
    {
      "nct_id": "NCT03737812",
      "title": "A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Sclerosis (MS)"
      ],
      "interventions": [
        {
          "name": "elezanumab",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 123,
      "start_date": "2019-02-27",
      "completion_date": "2021-08-30",
      "has_results": true,
      "last_update_posted_date": "2023-12-21",
      "last_synced_at": "2026-07-24T03:09:18.441Z",
      "location_count": 30,
      "location_summary": "Phoenix, Arizona • Berkeley, California • Carlsbad, California + 24 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Carlsbad",
          "state": "California"
        },
        {
          "city": "Hanford",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03737812"
    },
    {
      "nct_id": "NCT02081352",
      "title": "A Comparative Efficacy Study of DermaPure™ to Treat Diabetic Foot Ulcers",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Diabetic Foot Ulcers"
      ],
      "interventions": [
        {
          "name": "DermaPure™",
          "type": "OTHER"
        },
        {
          "name": "Standard care",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "TRx Wound Care Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2014-08",
      "completion_date": "2017-02",
      "has_results": false,
      "last_update_posted_date": "2015-11-05",
      "last_synced_at": "2026-07-24T03:09:18.441Z",
      "location_count": 7,
      "location_summary": "Phoenix, Arizona • Miami, Florida • New York, New York + 3 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02081352"
    },
    {
      "nct_id": "NCT03039192",
      "title": "54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Depressive Disorder, Major"
      ],
      "interventions": [
        {
          "name": "Esketamine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Standard of Care",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 226,
      "start_date": "2017-06-09",
      "completion_date": "2018-12-18",
      "has_results": true,
      "last_update_posted_date": "2025-04-29",
      "last_synced_at": "2026-07-24T03:09:18.441Z",
      "location_count": 17,
      "location_summary": "Birmingham, Alabama • Chandler, Arizona • Garden Grove, California + 14 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03039192"
    },
    {
      "nct_id": "NCT06186219",
      "title": "Recapturing Immune Tolerance to Pegloticase for the Management of Tophaceous Gout",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Tophaceous Gout"
      ],
      "interventions": [
        {
          "name": "Rituximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2024-04-10",
      "completion_date": "2024-11-22",
      "has_results": false,
      "last_update_posted_date": "2025-11-20",
      "last_synced_at": "2026-07-24T03:09:18.441Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06186219"
    },
    {
      "nct_id": "NCT01206101",
      "title": "Efficacy and Safety of Liraglutide in Subjects With Type 1 Diabetes Undergoing Islet Cell Transplantation",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetes",
        "Diabetes Mellitus, Type 1"
      ],
      "interventions": [
        {
          "name": "liraglutide",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2012-03-21",
      "completion_date": "2013-06-03",
      "has_results": true,
      "last_update_posted_date": "2017-03-30",
      "last_synced_at": "2026-07-24T03:09:18.441Z",
      "location_count": 4,
      "location_summary": "Duarte, California • Chicago, Illinois • Boston, Massachusetts + 1 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01206101"
    },
    {
      "nct_id": "NCT05126277",
      "title": "Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Lupus Nephritis"
      ],
      "interventions": [
        {
          "name": "ianalumab s.c. q4w",
          "type": "DRUG"
        },
        {
          "name": "ianalumab s.c. q12w",
          "type": "DRUG"
        },
        {
          "name": "placebo s.c.",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 452,
      "start_date": "2022-07-14",
      "completion_date": "2031-02-11",
      "has_results": false,
      "last_update_posted_date": "2026-05-22",
      "last_synced_at": "2026-07-24T03:09:18.441Z",
      "location_count": 27,
      "location_summary": "Birmingham, Alabama • La Palma, California • Orange, California + 21 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "La Palma",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05126277"
    },
    {
      "nct_id": "NCT02905565",
      "title": "NBP in Adult Patients With Acute Ischemic Stroke (AIS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "AIS"
      ],
      "interventions": [
        {
          "name": "NBP Softgel Capsules",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "CSPC-NBP Pharmaceutical Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 177,
      "start_date": "2018-02-28",
      "completion_date": "2020-08-07",
      "has_results": false,
      "last_update_posted_date": "2020-09-17",
      "last_synced_at": "2026-07-24T03:09:18.441Z",
      "location_count": 21,
      "location_summary": "Los Angeles, California • Jacksonville, Florida • Des Moines, Iowa + 15 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Des Moines",
          "state": "Iowa"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02905565"
    }
  ]
}